top of page

Safety specification

    This part of an RMP provides a synopsis of a medicinal product’s safety. It should be a summary of:
    • The important identified risks
    • Important potential risks
    • Missing information
    It should also address:
    • Populations potentially at risk (where the product is likely to be used in labelled and off-labelled use)
    • Safety questions which warrant further investigation during the post-authorization period
bottom of page